Compare BTU & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | IRON |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | 6600 | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | 2001 | 2020 |
| Metric | BTU | IRON |
|---|---|---|
| Price | $25.22 | $68.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $32.83 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 2.1M | 463.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,861,500,000.00 | N/A |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $5.47 | $283.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.06 | $40.00 |
| 52 Week High | $41.14 | $99.50 |
| Indicator | BTU | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 41.63 | 30.34 |
| Support Level | $25.20 | $64.48 |
| Resistance Level | $31.88 | $71.85 |
| Average True Range (ATR) | 1.20 | 3.16 |
| MACD | -0.48 | -1.20 |
| Stochastic Oscillator | 1.81 | 12.42 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.